Catalyst
Slingshot members are tracking this event:
Alder (ALDR) Presents Positive Data from Phase 2 Proof-of-Concept Study of ALD403 for the Prevention of Episodic Migraine
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALDR |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 15, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2 Proof-of-concept, Ald403, Episodic Migraine
